Bone Tissue Sarcoma Treatment Market

Bone Tissue Sarcoma Treatment Market: Introduction

Sarcomas are a heterogeneous group of rare cancers of mesenchymal origin. Bone tissue sarcoma is a cancer that occurs in bones and muscles. It is a tumor that develops in bone tissues. This tumor can occur randomly in any bone inside the body. Patients with bone cancer could experience bone pain, swelling, fatigue, and weight loss. The most common sarcomas include osteosarcoma and chondrosarcoma.

Most frequently diagnosed form of primary bone cancer is Ewing sarcoma, which mostly occurs in children and young adults. The disease can occur at any stage of an individual, but it is very uncommon in people over 30 years of age.

Sarcomas can be treated by various methods, including surgery, radiation, and chemotherapy. Currently, targeted therapies, in which only the damaged cells are targeted and normal cells are not affected, are in trend.

Key Drivers and Opportunities of Global Bone Tissue Sarcoma Treatment Market

• The Covid-19 pandemic has had a significant impact on surgical procedures, chemotherapy timings, frequent hospital visits, and osteosarcoma surgery schedules. In the bone cancer type segment of the market, among all other bone cancers, osteosarcoma is expected to have the highest market share during the forecast period.
• Osteosarcoma is the most common type of cancer which affects the bones, and it mostly occurs in children and young adults. Osteosarcoma is classified as high-, intermediate, or low-grade. According to the American Cancer Society (2019), about 850 to 900 new cases of cancer are reported in the U.S. every year.
• The bone tissue sarcoma treatment market is hampered by insufficient knowledge and lack of expertise in developing and least developed countries such as Kenya and India
• Various medical centres, university hospitals, and other institutions across the world are carrying out research on sarcoma. Considerable advancements have taken place in the last few decades in treating osteosarcoma. Osteosarcoma can be treated by various methods, including radiation therapy, surgery, and chemotherapy.

Therefore, research related to bone tissue sarcoma treatment is at its peak

North America to Capture Major Share of Global Bone Tissue Sarcoma Treatment Market

In terms of region, the global bone tissue sarcoma market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

In North America, the pandemic has significantly affected the US, which has led to disruptions in surgical procedures. Currently, precautionary measures are taken during surgical procedures, which would lead to steady market expansion.

North America currently captures a major share of the bone tissue sarcoma treatment market, and is expected to continue it for the next few years. A number of clinical trials are underway for bone cancer therapies, especially in the U.S., which is expected to increase its market share in the near future. New chemo drugs are currently in the trial phase. Researchers are looking for new ways to improve the approved drug portfolio. Experts are studying whether the addition of bisphosphonates such as zoledronic acid to bone cement could reduce the chances of tumor recurrence.

In Europe, methotrexate has been accepted as a standard agent. Apart from methotrexate, mifanurtide has been approved for the treatment of patients undergoing osteosarcoma.

Key Players Operating in Global Bone Tissue Sarcoma Treatment Market

The global bone tissue sarcoma market is highly concentrated due to presence of key players. A large number of manufacturers hold major shares in their respective regions. Demand for bone tissue sarcoma treatment has increased in emerging as well as developed markets due to rise in awareness about technologically advanced products. Growth strategies adopted by leading players are likely to drive the global market. Major players operating in the global bone tissue sarcoma treatment market are listed below:

• Amgen Inc.
• Bayer AG
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson Services Inc.
• Eli Lilly
• Debiopharm Group
• Takeda Pharmaceutical Company Ltd.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical
• Merck & Co
• Bristol-Myers Squibb Company

Global Bone Tissue Sarcoma Treatment Market: Research Scope

Global Bone Tissue Sarcoma Treatment Market, by Type

• Multiple Myeloma
• Osteosarcoma
•  Chondrosarcoma
• Ewing’s Sarcoma

Global Bone Tissue Sarcoma Treatment Market, by Treatment Type

• Targeted Therapy
•  Chemotherapy
• Radiation Therapy
• Other therapies

Global Bone Tissue Sarcoma Treatment Market, by End-user

• Hospitals
•  Clinics
• Diagnostic centres
• Others

Global Bone Tissue Sarcoma Treatment Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa